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Abstract 
Background: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegra‑
vir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment‑experienced patients 
from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).
Methods: Treatment‑experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 
2014–2018 and with more than 24 weeks of follow‑up were included. TFV could be administered either as tenofovir 
disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/
ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml 
at the start of the regimen).
Results: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 
(74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml 
at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline 
VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 
48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with base‑
line VL ≥ 50 copies/ml) changed due to virological failure.
Conclusions: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment‑experienced patients with 
undetectable viral load as a simplification strategy, allowing once‑daily, two‑pill regimen with three antiretroviral drug 
classes. Effectiveness was low in patients with detectable viral loads.
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Background
Treatment adherence is crucial for the effectiveness 
of antiretroviral therapy (ART) among HIV-infected 
patients. Adherence could be impaired with antiretro-
viral regimens that entail multiple pills or more than 
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once-daily dosing [1]; this is a frequent situation among 
patients with drug-resistant HIV. Simplification of com-
plex ART regimens is an important strategy for reducing 
the number of pills or doses per day and is intended to 
improve patients’ adherence and quality of life without 
compromising treatment effectiveness [2].
The fixed-dose combinations elvitegravir/cobicistat/
tenofovir disoproxil fumarate/emtricitabine (EVG/COB/
TDF/FTC,  Stribild®) and elvitegravir/cobicistat/teno-
fovir alafenamide/emtricitabine (EVG/COB/TAF/FTC, 
 Genvoya®) have been extensively used for the treatment 
of HIV-infected adults [3, 4]. The association of one of 
those fixed-dose combinations with darunavir 800  mg 
(DRV) would allow a once-daily, two-pill regimen that 
includes three classes of antiretroviral drugs and could be 
used to treat selected patients with drug-resistant HIV. 
This is an off-label indication.
With these combinations, COB, which boosts EVG, 
would also allow boosting of DRV [5]. However, phar-
macokinetic studies evaluating drug levels in patients 
receiving EVG/COB/TDF/FTC plus DRV have found 
conflicting results. While some studies have found lower 
levels of DRV and EVG in patients receiving EVG/COB/
TDF/FTC + DRV compared to those receiving each drug 
as a separate component (DRV being boosted either with 
COB or ritonavir) [6, 7], others found similar DRV and 
EVG levels in patients receiving this combination com-
pared to those receiving each separate drug [8, 9]. All 
these studies involved a very low number of patients 
(between 5 and 24).
The efficacy of EVG/COB/TAF/FTC + DRV in virologi-
cally suppressed patients was demonstrated in an open-
label clinical trial, which showed that switching to EVG/
COB/TAF/FTC + DRV was non-inferior to maintaining 
the previous ART at 24 weeks and superior at 48 weeks 
[10]. However, in spite of the results of this clinical trial 
and the potential advantages of this combination for ART 
simplification, there is very little evidence in real-life clin-
ical practice. Only three single-centre cohort studies ana-
lysing EVG/COB/TDF/FTC + DRV have been published, 
involving a very low number of patients (21, 10, and 17 
patients) and with limited follow-up [5, 6, 11].
Given the very scarce evidence with the combina-
tions EVG/COB/TDF/FTC + DRV and EVG/COB/TAF/
FTC + DRV in clinical practice, the conflicting results 
of pharmacokinetic studies, and the potential advan-
tages of these combinations as a simplification strategy, 
we designed a study to describe the use of elvitegravir/
cobicistat/tenofovir (administered either as disoproxil 
fumarate or alafenamide)/emtricitabine plus darunavir 
800  mg (EVG/COB/TFV/FTC + DRV) and analyse its 
effectiveness and tolerability in the multicentre Cohort of 
the Spanish HIV/AIDS Research Network (CoRIS). The 
specific objectives of the study were: (1) to describe the 
patients initiating EVG/COB/TFV/FTC + DRV and the 
reasons for starting this regimen, (2) to describe the tox-
icity of this regimen among patients who stopped it due 
to adverse events, and (3) to describe the effectiveness of 
EVG/COB/TFV/FTC + DRV in terms of viral suppres-
sion and change in CD4 count at 24 and 48 weeks after 
starting this regimen.
Methods
Patients were selected from the Cohort of the Spanish 
HIV/AIDS Research Network (CoRIS), which has been 
described in detail elsewhere [12, 13]. CoRIS is a pro-
spective multicentre cohort of adult HIV-positive treat-
ment-naïve patients, recruited from 46 centres from 13 
Autonomous Regions in the Spanish public healthcare 
system. Since January 2004 to the last update in Novem-
ber 2018, 15509 patients have been recruited in CoRIS.
We included all treatment-experienced patients who 
started treatment with EVG/COB/TFV/FTC + DRV 
from January 2014 to November 2018 and who had more 
than 24 weeks of follow-up. TFV could be administered 
either as tenofovir disoproxil fumarate or tenofovir 
alafenamide.
We collected information on the following variables: 
age, sex, mode of HIV transmission (men who have sex 
with men [MSM], heterosexual, injecting drug user 
[IDU], other/unknown), country of origin (Spanish, for-
eign-born), CD4 count and viral load at the start of EVG/
COB/TFV/FTC + DRV and at 24 and 48  weeks after 
starting this regimen (± 12 weeks), reasons for stopping 
the previous treatment and EVG/COB/TFV/FTC + DRV 
(simplification, virological failure, toxicity, interactions, 
other, unknown) and regimen to which it was switched, 
previous antiretroviral regimens, number of pills and 
doses per day with the previous antiretroviral regimen, 
and time since the start of the first ART.
Descriptive analyses were carried out using fre-
quency tables for categorical variables and median 
and interquartile range (IQR) for continuous vari-
ables. For the analysis of treatment effectiveness, the 
primary endpoint was the proportion of patients with 
virological response, defined as viral load < 50  copies/
ml at 24 and 48  weeks after starting EVG/COB/TFV/
FTC + DRV. Since the threshold of 200  copies/ml is 
used in several guidelines to define virologic failure 
[14, 15], we also analysed a secondary endpoint of viro-
logical response defined as viral load < 200 copies at 24 
and 48  weeks. We also evaluated the median change 
in CD4 count at 24 and 48  weeks, and the propor-
tion of patients stopping their treatment due to viro-
logical failure and due to adverse events. Results were 
stratified by baseline viral load (< 50 or ≥ 50  copies/
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ml): baseline was defined as the time of the initiation 
of EVG/COB/TFV/FTC + DRV. For the endpoints of 
virological response and change in CD4 count, we per-
formed an intention to treat analysis: therefore, once 
the treatment was started, all patients were assumed to 
remain on it and subsequent changes were ignored.
Statistical analyses were performed in Stata soft-
ware (version 14.0; Stata Corporation, College Station, 
Texas, USA). All patients signed informed consent 
forms. The study was approved by the Ethics Commit-
tee of Instituto de Salud Carlos III (Madrid).
Results
During the study period, 39 patients from 11 centres 
switched their ART to the regimen EVG/COB/TFV/
FTC + DRV. Patients’ demographic and clinical char-
acteristics are shown in Table 1. At the start of the reg-
imen, tenofovir was administered as TDF in 16 and as 
TAF in 23 patients. During follow-up, eight of the 16 
patients who started the regimen with TDF switched 
TDF to TAF as part of the same regimen.
At baseline, 10 (25.6%) patients were virologically 
suppressed and 29 (74.4%) patients had detectable 
viral load. The most frequent reasons for changing to 
this regimen were virological failure and treatment 
simplification (Table 1).
The patients received EVG/COB/TFV/FTC + DRV 
for a median of 391 (IQR: 205 to 514) days. Outcomes 
at 24 and 48 weeks are shown in Table 2.
Among virologically suppressed patients at base-
line, 85.7% and 80.0% of the patients achieved viral 
load < 50 copies/ml at 24 and 48  weeks, respectively. 
However, among patients with detectable baseline viral 
load, only 42.3% and 40.9% achieved these endpoints, 
respectively. The percentages of patients achieving 
viral load < 200/ml at 24 and 48 weeks were higher for 
both groups and reached 100% among the patients 
who were virologically suppressed at baseline.
The number of patients who changed their treat-
ment during the first 24 and 48  weeks, stratified by 
baseline viral load, is shown in Table  2. Among the 
two virologically suppressed patients at baseline who 
changed their treatment during the first 48 weeks, the 
reasons were simplification in 1 patient and unknown 
in 1 patient. Among patients with baseline detectable 
viral load, the reasons for changing the regimen during 
the first 24  weeks were failure in 4, simplification in 
3, and non-adherence in 1 patient, and the reasons for 
changing the regimen during the first 48  weeks were 
simplification in 7 patients, failure in 4 patients, non-
adherence in 1 patient, and unknown in 1 patient.
Discussion
This study has analysed the largest cohort published to 
date showing results from “real-world” clinical prac-
tice with the regimen EVG/COB/TFV/FTC + DRV. In 
our study, EVG/COB/TFV/FTC + DRV was well toler-
ated and effective in treatment-experienced patients 
with baseline undetectable viral load as a simplification 
strategy, allowing a once-daily, two-pill regimen with 
three antiretroviral drug classes. However, effectiveness 
was low in patients with baseline detectable viral loads.
There is only one open-label clinical trial that 
assessed the efficacy of this regimen, which analysed 
135 treatment-experienced, virologically suppressed 
patients who were randomized to continue their pre-
vious ART or change to EVG/COB/TAF/FTC + DRV. 
The study found that this combination had high effi-
cacy (96.6%) and was noninferior to maintaining the 
Table 1 Patients’ characteristics at  the  start of  EVG/COB/
TFV/FTC + DRV (n = 39)
Values are expressed as n/total (%) unless stated otherwise
IQR Interquartile range
Age, median (IQR), years 42 (34–50)
Female 5 (12.8)
Mode of transmission
 Men who have sex with men 19 (48.7)
 Heterosexual 13 (33.3)
 Injecting drug user 5 (12.8)
 Other/unknown 2 (5.1)
Geographic origin
 Spanish 14 (33.3)
 Foreign‑born 24 (61.5)
  Unknown 1 (2.4)
 Viral load, median (IQR), copies/ml 379 (40–12,000)
 CD4 count, median (IQR), cells/microl 437 (108–740)
Viral load
 < 50 copies/ml 10 (25.6)
 ≥ 50 copies/ml 29 (74.4)
 Years since starting ART, median (IQR) 5.3 (2.5–7.5)
 Number of prior regimens, median (IQR) 3 (2–6)
Previous ART regimen
 ART daily pill burden, median (IQR) 2 (1–5)
 At least 3 pills per day 17 (43.6)
 At least twice daily ART dosing 11 (28.2)
Reasons for switching to EVG/COB/TFV/FTC + DRV
 Virologic failure 14 (35.9)
 Simplification 10 (25.6)
 Toxicity 4 (10.3)
 Non‑adherence 2 (5.1)
 Unknown 9 (23.1)
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previous ART at 24  weeks and superior at 48  weeks 
[10]. However, it is necessary to contrast the findings 
from clinical trials with real-world data, such as those 
obtained from cohort studies: clinical trials include 
selected patients that are often different from those of 
the population who will receive those treatments (such 
as lower number of patients with severe immunosup-
pression, elderly patients, or those with co-morbid-
ities), and provide more intensive monitoring to the 
patients (which could influence adherence to treatment 
and detection of adverse effects), limiting the generaliz-
ability of their findings [16, 17].
Regarding real-world data, the evidence for the effec-
tiveness of this regimen is very limited: only three cohort 
studies have been published analysing EVG/COB/TDF/
FTC + DRV, all from single centres, involving a very low 
number of patients, and analysing different endpoints. 
The effectiveness was high in the three studies: Naccarato 
et  al. evaluated 21 treatment-experienced patients (29% 
of which were virologically suppressed before the switch) 
who received EVG/COB/TDF/FTC + DRV: at week 48, 
14 (67%) patients had undetectable viral load, 1 had viro-
logic failure (> 40 copies/ml) and 6 had stopped the treat-
ment or had no viral load data [5]. Harris et al. evaluated 
the simplification to the same regimen in 10 virologi-
cally suppressed patients: 8 of them had viral loads < 40 
copies/ml at weeks 24 and 48 and all of them had viral 
loads < 200 copies/ml up to week 48 [6]. The last study by 
Diaz et al. found that 15 (88%) of 17 patients (naïve and 
treatment-experienced) had viral loads < 50  copies/ml at 
week 24 [11].
In our study, the effectiveness of EVG/COB/TFV/
FTC + DRV was high in patients who were virologically 
suppressed at baseline: 85.7% and 80.0% of the patients 
had viral loads < 50 copies at 24 and 48  weeks, respec-
tively, and 100% of the patients had viral loads < 200 cop-
ies/ml at 24 and 48 weeks. These results are comparable 
to the studies mentioned above. However, the effective-
ness was much lower for patients who had detectable 
viral loads at baseline. These results suggest that this regi-
men has high effectiveness as a switch strategy for viro-
logically suppressed patients, but it should not be used in 
patients with virological failure if other alternatives exist. 
Overall, the treatment was well tolerated in both groups, 
as none of the patients discontinued their treatment due 
to toxicity. The treatment also allowed to decrease the pill 
burden in 43.6% of the patients and the number of doses 
per day in 28.2%.
For the combination EVG/COB/TFV/FTC + DRV, our 
patients were receiving tenofovir either as alafenamide or 
as disoproxil fumarate. Also, as EVG/COB/TAF/FTC was 
commercialized in Spain in May 2016, many patients who 
were receiving EVG/COB/TDF/FTC changed their treat-
ment to EVG/COB/TAF/FTC in order to minimize the 
Table 2 Outcomes of  patients at  24 and  48  weeks after  starting EVG/COB/TFV/FTC + DRV, stratified by  viral load 
at the start of the regimen
Values are expressed as n/total (%) unless stated otherwise
IQR Interquartile range
Outcome 24 weeks 48 weeks
Virological response < 50 copies/ml
 Viral load < 50 copies/ml 6/7 (85.7) 4/5 (80.0)
 Viral load ≥ 50 copies/ml 11/26 (42.3) 9/22 (40.9)
Virological response < 200 copies/ml
 Viral load < 50 copies/ml 7/7 (100.0) 5/5 (100.0)
 Viral load ≥ 50 copies/ml 18/26 (69.2) 15/22 (68.2)
CD4 change, cells/microl: median (IQR)
 Viral load < 50 copies/ml 29 (14–48) 8 (− 85–50)
 Viral load ≥ 50 copies/ml − 6 (− 134–107) − 16 (− 116–77)
Patients stopping the regimen for any reason
 Viral load < 50 copies/ml 0/10 (0) 2/10 (20.0)
 Viral load ≥ 50 copies/ml 8/29 (27.6) 13/29 (44.8)
Patients stopping the regimen due to treatment failure
 Viral load < 50 copies/ml 0/10 (0) 0/10 (0)
 Viral load ≥ 50 copies/ml 4/29 (13.8) 4/29 (13.8)
Patients stopping the regimen due to toxicity
 Viral load < 50 copies/ml 0/10 (0) 0/10 (0)
 Viral load ≥ 50 copies/ml 0/29 (0) 0/29 (0)
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risk of renal and bone toxicity, as did 8 of our patients. 
Given that the treatment with EVG/COB/TAF/FTC has 
shown non-inferiority compared to EVG/COB/TDF/
FTC in clinical trials [3, 4], we have analysed our results 
combining both treatments. To ensure that this was 
an adequate strategy, we repeated our analysis stratify-
ing by treatment with TAF or TDF: the results were not 
changed (data not shown).
Our study has the limitation of low sample size. Also, 
since CoRIS does not routinely record resistance testing 
in pre-treated patients, we could not describe accumu-
lated resistance mutations or those arising after failure 
with this regimen. Another limitation is that we cannot 
give information on patients’ adherence as CoRIS does 
not routinely record this variable. However, this is the 
largest cohort published to date analysing this treatment 
regimen, with a reasonable follow-up time, and it gives 
information from routine clinical practice for a com-
bination that could be potentially useful for treatment 
simplification and has very little published evidence. 
Our strengths include the use of a multicentre cohort 
with rigorous quality control and which has clinical and 
demographic characteristics that are similar to the ones 
from the general population reported by the National 
HIV Surveillance System [18].
Conclusion
The combination EVG/COB/TFV/FTC + DRV is an 
effective, well tolerated strategy for treatment simplifica-
tion in virologically suppressed patients. This treatment 
is not suitable, however, for treatment-experienced indi-
viduals with detectable viral loads, given the low efficacy 
in this group of patients.
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Hospital Universitario Virgen del Rocío (Sevilla): Pompeyo Viciana, Nuria 
Espinosa, Luis Fernando López‑Cortés.
Hospital Universitario de Bellvitge (Hospitalet de Llobregat): Daniel Podzamc‑
zer, Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy, Paula Prieto.
Hospital Universitario Valle de Hebrón (Barcelona): Esteban Ribera, Adrian 
Curran.
Hospital Costa del Sol (Marbella): Julián Olalla Sierra, Javier Pérez Sta‑
chowski., Alfonso del Arco, Javier de la torre, José Luis Prada, José María García 
de Lomas Guerrero.
Hospital General Universitario Santa Lucía (Cartagena): Onofre Juan Mar‑
tínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, 
Amaya Jimeno.
Complejo Hospitalario Universitario a Coruña (Chuac) (A Coruña): Angeles 
Castro Iglesias, Berta Pernas Souto, Alvaro Mena de Cea.
Hospital Universitario Basurto (Bilbao): Josefa Muñoz, Miren Zuriñe Zubero, 
Josu Mirena Baraia‑Etxaburu, Sofía Ibarra Ugarte, Oscar Luis Ferrero Beneitez, 
Josefina López de Munain, Mª Mar Cámara López, Mireia de la Peña, Miriam 
Lopez., Iñigo Lopez Azkarreta.
Hospital Universitario Virgen de la Arrixaca (El Palmar): Carlos Galera, Helena 
Albendin, Aurora Pérez, Asunción Iborra, Antonio Moreno, Maria Angustias 
Merlos, Asunción Vidal, Marisa Meca.
Hospital de la Marina Baixa (La Vila Joiosa): Concha Amador, Francisco 
Pasquau, Javier Ena, Concha Benito, Vicenta Fenoll., Concepcion Gil Anguita, 
Jose Tomas Algado Rabasa.
Hospital Universitario Infanta Sofia (San Sebastian de los Reyes): Inés Suárez‑
García, Eduardo Malmierca, Patricia González‑Ruano, Dolores Martín Rodrigo, 
Mª Pilar Ruiz Seco.,
Hospital Universitario de Jaén (Jaén): Mohamed Omar Mohamed‑Balghata, 
María Amparo Gómez Vidal.
Hospital San Agustín (Avilés): Miguel Alberto de Zarraga.
Hospital Clínico San Carlos (Madrid): Vicente Estrada Pérez, Maria Jesus Téllez 
Molina, Jorge Vergas García, Juncal Pérez‑Somarriba Moreno.
Hospital Universitario Fundación Jiménez Díaz (Madrid): Miguel Górgolas, 
Alfonso Cabello, Beatriz Álvarez, Laura Prieto.
Hospital Universitario Príncipe de Asturias (Alcalá de Henares): José Sanz 
Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella 
Mena.
Hospital Clínico Universitario de Valencia (València): María José Galindo 
Puerto, Ramón Fernando Vilalta, Ana Ferrer Ribera.
Hospital Reina Sofía (Córdoba): Antonio Rivero Román, Antonio Rivero 
Juárez, Pedro López López, Isabel Machuca Sánchez, Mario Frias Casas, Angela 
Camacho Espejo.
Hospital Universitario Severo Ochoa (Leganés): Miguel Cervero Jiménez, 
Rafael Torres Perea.
Nuestra Señora de Valme (Sevilla): Juan A Pineda, Pilar Rincón Mayo, Juan 
Macias Sanchez, Nicolas Merchante Gutierrez, Luis Miguel Real, Anais Corma 
Gomez, Marta Fernandez Fuertes, Alejandro Gonzalez‑Serna.
Hospital Álvaro Cunqueiro (Vigo): Eva Poveda, Alexandre Pérez, Manuel 
Crespo, Luis Morano, Celia Miralles, Antonio Ocampo, Guillermo Pousada.
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